Navigation Links
Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
Date:4/6/2009

CHICAGO - An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer. Thoracic surgeons at Rush University Medical Center are researching the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is designed to kill cancer cells without harming normal cells. Rush is one of only five hospitals in Illinois offering the vaccine.

The MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell LunG Cancer Immunotherapy) study is a randomized, double-blind and placebo controlled trial that will enroll patients with MAGE A-3-positive, non-small-cell lung cancers. The experimental vaccine targets MAGE-A3, a protein expressed in certain cancer cells but not in normal cells. Thirty-five percent of non-small-cell lung cancers have this protein which also is present in some melanomas and head and neck cancers.

"The principle is that you can possibly teach a patient's immune system to eliminate cancer cells that express certain proteins such as the MAGE-A3 protein," said Dr. Anthony Kim, thoracic surgeon and principal investigator of the study at Rush. "In a trial of early-stage lung cancer patients whose tumors expressed MAGE-A3, preliminary results showed that the vaccination reduced the risk of recurrence and the need for repeat surgery."

The vaccination may be a promising alternative treatment solution for lung cancer patients that may not be ideal candidates for chemotherapy. Many surgically treated lung cancer patients are not able to tolerate the side effects of chemotherapy.

Surgery is the standard treatment for patients with early-stage lung cancer, but approximately 50 percent of patients who have surgery ultimately die of lung cancer.

"Adding the tumor vaccine to surgery has the potential to boost the survival rate by 10 percent, which was the figure that was observed in the initial phase of the
'/>"/>

Contact: Deborah Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. MIT: Novel needle could cut medical complications
2. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
3. Novel electric signals in plants
4. Novel veterinary procedure detecting life-threatening injuries touted
5. Forget the freezer: Research suggests novel way to control water behavior
6. Breaking the barrier: Discovery of anti-resistance factors and novel ocean drugs
7. Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family
8. Fighting obesity and illness with a novel approach to nutrition
9. Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon)
10. Novel technology could produce biofuel for around €0.50 a liter ($2.49 a gallon)
11. Studies point to novel target for treating arrhythmias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... a species of alfalfa from Siberia, to the United States. His ... But what also happened during this time in the late ... of the matter is creating a current revival in both interest ... And several researchers members of the American Society of Agronomy (ASA) ...
... 31st, 2012.- Madrid will become international destination for ... Innovation Conference 2012, focused on building high performance ... This new organization has been created by the ... Government of the Comunidad de Madrid, through the ...
... CRUZ, CA--Researchers at the University of California, Santa Cruz, ... from wounds and skin infections, using light to trigger ... developed a photoactive compound that releases nitric oxide when ... biocompatible material that could be applied as a sprayable ...
Cached Biology News:Time is ticking for some crop's wild relatives 2MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 3
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)... Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ... treat life-threatening diseases, today announced that it will host ... webcast on Thursday, August 13, 2015 at 4:30 p.m. ... follow the release of fiscal 2016 first quarter results.  ... approximately two hours after the call at the Investor ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... ... ... Xybion Corporation announced today that it has completed the acquisition of substantially all of ... The terms of the transactions were not disclosed., , ,Stelex and Vital-Path, based in Bensalem, ...
... CHENGDU, China , May 12 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... in the modernized traditional Chinese medicine ("TCM") and branded,generics today announced ... , , Third quarter fiscal year 2010 ending ... revenue increased 60% year over year to $15.9 million, net, ...
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
Cached Biology Technology:Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 2Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 3Tianyin Reports Record Third Quarter 2010 Financial Results 2Tianyin Reports Record Third Quarter 2010 Financial Results 3Tianyin Reports Record Third Quarter 2010 Financial Results 4Tianyin Reports Record Third Quarter 2010 Financial Results 5Tianyin Reports Record Third Quarter 2010 Financial Results 6Tianyin Reports Record Third Quarter 2010 Financial Results 7Tianyin Reports Record Third Quarter 2010 Financial Results 8Tianyin Reports Record Third Quarter 2010 Financial Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 10Tianyin Reports Record Third Quarter 2010 Financial Results 11Tianyin Reports Record Third Quarter 2010 Financial Results 12Tianyin Reports Record Third Quarter 2010 Financial Results 13Quantum move toward next generation computing 2
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Biology Products: